Abstract:AIM:To evaluate the bioequivalence of ranitidine and bismuth derived from two compound preparations.METHODS:The bioavailability was measured in 20 healthy male Chinese volunteers following a single oral dose (equivalent to 200 mg of ranitidine and 220 mg of bismuth) of the test or reference products in the fasting state. Then blood samples were collected for 24 h. Plasma concentrations of ranitidine and bismuth were analyzed by high-performance liquid chromatography and inductively coupled plasma-mass spectrometry (ICP-MS), respectively. The non-compartmental method was used for pharmacokinetic analysis. Log-transformed C(max), AUC( (0-t) ) and AUC( (0-infinity) ) were tested for bioequivalence using ANOVA and Schuirmann two-one sided t-test. T(max) was analyzed by Wilcoxon's test.RESULTS:Various pharmacokinetic parameters of ranitidine derived from the two compound preparations, including C(max), AUC( (0-t)), AUC( (0-infinity)), T(max) and T((1/2)), were nearly consistent with previous observations. These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h). In addition, double-peak absorption profiles of ranitidine were found in some Chinese volunteers. For bismuth, those parameters derived from test and reference drug were as follows: C(max) (11.80 +/- 7.36 vs 11.40 +/- 6.55 microg/L), AUC( (0-t) ) (46.65 +/- 16.97 vs 47.03 +/- 21.49 microg/L per hour), T(max) (0.50 +/- 0.20 vs 0.50 +/- 0.20 h) and T((1/2)) (10.2 +/- 2.3 vs 13.0 +/- 6.9 h). Ninety percent of confidence intervals for the test/reference ratio of C(max), AUC( (0-t) ) and AUC( (0-infinity) ) derived from both ranitidine and bismuth were found within the bioequivalence acceptable range of 80%-125%. No significant difference was found in T(max) derived from both ranitidine and bismuth.CONCLUSION:The two compound preparations are bioequivalent and may be prescribed interchangeably.

Pharmacokinetics and Bioequivalence of Ranitidine and Bismuth Derived from Two Compound Preparations

Study on bioequivalence of cilostazol table in healthy volunteers

Bioequivalence of Domestic and Imported Nizatidine Formulations in Chinese Healthy Volunteers

Bioequivalence Evaluation of Two Rabeprazole Enteric Coated Formulations in Healthy Chinese Volunteers

Bioequivalence of Two Nizatidine Capsules in Healthy Volunteers

Pharmacokinetics and Bioequivalence of 2 Kinds of Amoxicillin Dispersible Tablets in Healthy Volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Study on the Pharmacokinetics and Bioequivalence of Isosorbide 5-Mononitrate and Aspirin from Compound Isosorbide Mononitrate Sustained Release Tablets in Healthy Volunteers

Research and Bioequivalence of Ibuprofen Liquid Suspension

Bioequivalence of trimetazidine dihydrochloride tablets in Chinese healthy subjects

Pharmacokinetics and Bioequivalence of a Generic and a Branded Budesonide Nasal Spray in Healthy Chinese Subjects

Bioequivalent assessment of imported arginine and ibuprofen granules

Bioequivalence of Pantoprazole Sodium Enteric-Coated Capsules in Human

Evaluation of the bioequivalence and pharmacokinetics of two formulations of secnidazole after single oral administration in healthy volunteers

Bioequivalence of Clarithromycin Dispersed Tablet in Health Volunteers

Pharmacokinetics and bioequivalence evaluation of two oral formulations of cotrimoxazole tablets in healthy Chinese volunteers under fasting conditions

Bioequivalence of Amoxycillin-Clavulanic Acid Tablet and Suspension

The relative bioavailability of allopurinol tablets in man

Effervescent and standard formulations of ranitidine--a comparison of their pharmacokinetics and pharmacology

Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers

A crossover study to evaluate the pharmacokinetics and bioequivalence of hydroxychloroquine tablets in healthy Chinese subjects